Contact Us

Get 30% Free Customization on This Report

Published Date: April, 2019

Monoclonal Antibody Therapeutics Market (End Users - Research Institute, Private Clinics, Hospitals; Based on Source - Humanized, Human, Chimeric, and Others; Application - Cancer, Ophthalmological Diseases, Hematological Diseases, Infectious Diseases, Autoimmune Diseases, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025


Request Discount Enquire Before Buying

A recent report published by Infinium Global Research on monoclonal antibody therapeutics market provides in-depth analysis of segments and sub-segments in the global as well as regional monoclonal antibody therapeutics market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional monoclonal antibody therapeutics market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global monoclonal antibody therapeutics market. According to the report, the global monoclonal antibody therapeutics market is projected to grow at a CAGR of 12.80% over the forecast period of 2019-2025.

 

Market Insight

A monoclonal antibody therapeutics is a form of immunotherapy that helps in stimulating the patient's immune system and it prevents tumor growth by blocking specific cell receptors. Monoclonal antibodies based therapeutics are growing with the advent of mammalian cell culture, process, and formulation technology. Monoclonal antibodies are used in the treatment of several major diseases such as cardiovascular and infectious diseases, autoimmune, cancer and inflammation.

 

Growing adoption of monoclonal antibody therapeutics in cancer treatments drives the growth of monoclonal antibody therapeutics market. Monoclonal antibody drugs procure natural immune system to fight cancer. Monoclonal antibodies are beneficial to treat cancer in several ways as it blocks the cell growth, flagging cancer cells prevents blood vessel growth and blocks immune system inhibitors. Furthermore, rising use of monoclonal antibodies for the treatment of autoimmune diseases particularly in rheumatoid arthritis and multiple sclerosis boosts the growth of monoclonal antibody therapeutics market. Rapid development in the hybridoma technique and increasing approvals of monoclonal antibodies for the treatment of several diseases contribute to the growth of monoclonal antibody therapeutics market. Increasing prevalence of Alzheimer's disease, cancer, autoimmune diseases and growing awareness regarding several diseases fuels the growth of monoclonal antibody therapeutics market. However, the high cost of monoclonal antibodies may hamper the growth of monoclonal antibody therapeutics market. Moreover, increasing investment in research and development, as well as drug approvals for the treatment of several diseases, provides beneficial opportunities for the monoclonal antibody therapeutics market.

 

Geographically, North America dominated the monoclonal antibody therapeutics market. Approval of monoclonal antibodies by the US FDA, development in healthcare infrastructure, huge expenditure and investment in research and development activities contribute to the growth of monoclonal antibody therapeutics market in the region. According to a recent study by American Cancer Society researchers, at least 42% of newly diagnosed cancers in the US, about 740,000 cases in 2019. The monoclonal antibody therapeutics market in the Asia Pacific region is expected to grow at a moderate rate, owing to increasing population and awareness of several diseases and treatments, as well as increasing healthcare expenditure in the region. According to the world health organization, cancer is the second leading cause of death globally and is estimated to account for 9.6 million death in 2018. Europe accounts for 23.4% of the global cancer cases and 20.3% of cancer deaths.


Global Monoclonal Antibody Therapeutics Market

 

Segment Covered

The report on global monoclonal antibody therapeutics market covers segments such as end users, based on source, and application. On the basis of end users, the sub-markets include research institute, private clinics, and hospitals. On the basis of based on source, the sub-markets include humanized, human, chimeric, and others. On the basis of application, the sub-markets include cancer, ophthalmological diseases, hematological diseases, infectious diseases, autoimmune diseases, and others.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Novartis AG, Amgen Inc., AbbVie Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Sanofi, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bayer AG, and GlaxoSmithKline Plc.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of monoclonal antibody therapeutics market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

The Infinium Advantages

Analyst Support

Get free analyst support for the queries before and post purchasing report.

Customer Satisfaction

Be assured of 100% customer satisfaction about the research and get 24X7 customer support.

400% Growth

Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.

Related Reports

sign up for our newsletter